期刊文献+

两种不同中医证型的癌痛患者在吗啡滴定中差异性研究

下载PDF
导出
摘要 目的研究中医证候与吗啡滴定过程的相关性以及两种不同中医证型在吗啡滴定过程中有无差异。方法入组的气血亏虚证和热毒内蕴证癌痛患者共74例,分别进行口服吗啡滴定,直至疼痛控制(NRS≤3),记录达到疼痛控制所需滴定次数及吗啡使用总剂量,采用SPSS19.0软件进行统计学分析。结果 41例气血亏虚证患者就诊时疼痛程度平均(5.07±1.13)分,平均滴定次数为(4.39±0.83)次,完成滴定的平均吗啡总剂量为(24.76±9.15)mg。33例热毒内蕴证患者疼痛程度平均(5.85±1.00)分,平均滴定次数(4.87±0.60)次,完成滴定的平均吗啡总剂量为(33.48±10.93)mg。经t检验,P均<0.05,差异有统计学意义。结论气血亏虚证的平均疼痛程度较轻,平均滴定次数及吗啡总剂量上小于热毒内蕴证。
作者 王辉 方红明
机构地区 浙江萧山医院
出处 《福建中医药》 2015年第4期20-21,共2页 Fujian Journal of Traditional Chinese Medicine
  • 相关文献

参考文献8

  • 1COHEN M Z,EASLEY M K,ELLIS C ,et al.Caneer pain man- agement and the JCAHO's pain standards:an institutional chal- lenge [J]. J Pain Symptom Manage ,2003,25(6):519-527.
  • 2GOUDAS L C,BLOCH R,GIALELI-GOUDAS M,et al.The epi- demiology of cancer pain [J].Cancer Invest,2005,23 (2) :182- 190.
  • 3SVENDSEN K B,ANDERSEN S,ARNASON S,et al. Breakthrough pain in malignant and non-malignant diseasers:a review of prevlence, characteristics and mechanisms[J]. Eur J Pain,2005,9(2) : 195-206.
  • 4HONGMING PAN,ZAIYUN ZHANG,YIPING ZHANG,et al. Ef- ficacy and tolerability of oxycodone HC 1 controlled-release tablets on moderate to severecancerpain [J]. Clin Drug Invest, 2007,27 (4) :259-267.
  • 5于世英.癌症疼痛诊疗规范(2011年版)[EB/OL].(2011—12—31)[2015-5-31].http://www.caea.org.cn/system,2012/06,11/011107045.shtml.
  • 6KOIZUMI W,TOMA H,WATANABE K,et al. Efficacy and toler- ability of cancer pain management with controlled-release oxyeodone tablets in pioidnaive cancer pain patients,starting with 5 mg tablets[J]. Jim J Clin Oncol,2004,34(10) :608-614.
  • 7张海鸥,方文怡,黄铭涵,胡光宏,王文荣,黄恒青,叶春荣.中西医结合提高中晚期胃癌患者生活质量的临床观察[J].福建中医药,2010,41(4):8-9. 被引量:9
  • 8薛娜,林洪生.中西医治疗癌症疼痛的现状及思考[J].现代肿瘤医学,2012,20(5):1072-1076. 被引量:8

二级参考文献35

  • 1SCHIPPER H. Treating cancer:is kill cure?[J]. Ann Aead Med Singapore, 1994,23 ( 3 ) : 382-386.
  • 2L Jost,F Roila.Management of cancer pain:ESMO clinical prac-tice guidelines[J].Ann Oncol,2010,21(supplement5):257-260.
  • 3S Deandrea,M Montanari,L Moja,et al.Prevalence of undertreat-ment in cancer pain.A review of published literature[J].Ann On-col,2008,19(12):1985-1991.
  • 4Tsugunobu ANDOH,Kenji SUGIYAMA,Masahide FUJITA,et al.Pharmacological evaluation of morphine and non-opioid analgesicadjuvants in a mouse model of skin cancer pain[J].Biol PharmBull,2008,31(3):520-522.
  • 5NI Cherny.How to deal with difficult pain problems[J].Ann On-col,2005,16(Supplement 2):ii79-ii87.
  • 6Marie Fallon,Geoffrey Hanks,Nathan Cherny.Principles of controlof cancer pain[J].BMJ,2006,332(29):1022-1024.
  • 7Cielito C,Reyes-Gibby,Badi El Osta,et al.The influence oftumor necrosis factor-A-308 G/A andIL-6-174 G/C onpain and analgesia response in lung cancer patients receiving sup-portive care[J].Cancer Epidemiol Biomarkers Prev,2008,17(6):3262-3267.
  • 8RE Coleman.Risks and benefits of bisphosphonates[J].Br J Canc-er,2008,98(11):1736-1740.
  • 9Pierrick G Fournier,Verena Stresing,Frank H Ebetino,et al.howdo bisphosphonates inhibit bone metastasis in vivo[J]?Neopla-sia,2010,12(7):571.
  • 10Darren J,Hillegonds,Stephen Franklin,et al.The management of painful bone metastases with an emphasis on radionuclide therapy[J].J Nati Med Association,2007,997(7):85-794.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部